# EDGAR Filing Document

**Accession Number:** 0001321834
**File Stem:** 0000000000-26-001037
**Filing Date:** 2026-1
**Character Count:** 2737
**Document Hash:** afb07f99fe86001c69799926127146d2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-001037.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0000000000-26-001037

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260128

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Q/C TECHNOLOGIES, INC.
- **CENTRAL INDEX KEY:** 0001321834
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08964

**BUSINESS ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS
- **STREET 2:** SUITE 249
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 856-848-8698

**MAIL ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS
- **STREET 2:** SUITE 249
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TNF Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20240725

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MyMD Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20210420

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Akers Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20170413
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-26-003372

## Text-Extract

```

                                                            January 28, 2026

Joshua Silverman
Executive Chairman
Q/C Technologies, Inc.
1185 Avenue of the Americas, Suite 249
New York, NY 10036

       Re: Q/C Technologies, Inc.
           Draft Registration Statement on Form S-3
           Submitted January 23, 2026
           CIK No. 0001321834
Dear Joshua Silverman:

       This is to advise you that we do not intend to review your registration
statement.

        We request that you publicly file your registration statement and
non-public draft
submission on EDGAR at least two business days prior to the requested effective
date and time.
Please refer to Rules 460 and 461 regarding requests for acceleration. We
remind you that the
company and its management are responsible for the accuracy and adequacy of
their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

       Please contact Tyler Howes at 202-551-3370 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:    Rick Werner, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._